Previous Article | Next Article 
Journal of Virology, March 2001, p. 2741-2752, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2741-2752.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Antibody Binding and Neutralization of Primary and T-Cell
Line-Adapted Isolates of Human Immunodeficiency Virus Type 1
Joanne
York,1
Kathryn E.
Follis,1
Meg
Trahey,1
Phillipe N.
Nyambi,2
Susan
Zolla-Pazner,2,3 and
Jack H.
Nunberg1,*
Montana Biotechnology Center, The University
of Montana, Missoula, Montana 598121;
New York University School of Medicine, New York, New York
100162; and Veterans Affairs Medical
Center, New York, New York 100103
Received 9 October 2000/Accepted 19 December 2000
The relative resistance of human immunodeficiency virus type 1 (HIV-1) primary isolates (PIs) to neutralization by a wide range of
antibodies remains a theoretical and practical barrier to the
development of an effective HIV vaccine. One model to account for the
differential neutralization sensitivity between Pls and laboratory (or
T-cell line-adapted [TCLA]) strains of HIV suggests that the envelope
protein (Env) complex is made more accessible to antibody binding as a
consequence of adaptation to growth in established cell lines. Here, we
revisit this question using genetically related PI and TCLA viruses and
molecularly cloned env genes. By using complementary
techniques of flow cytometry and virion binding assays, we show that
monoclonal antibodies targeting the V3 loop, CD4-binding site,
CD4-induced determinant of gp120, or the ectodomain of gp41 bind
equally well to PI and TCLA Env complexes, despite large differences in
neutralization outcome. The data suggest that the differential
neutralization sensitivity of PI and TCLA viruses may derive not from
differences in the initial antibody binding event but rather from
differences in the subsequent functioning of the PI and TCLA Envs
during virus entry. An understanding of these as yet undefined
differences may enhance our ability to generate broadly neutralizing
HIV vaccine immunogens.
*
Corresponding author. Mailing address: Montana
Biotechnology Center, The University of Montana, Missoula, MT
59812. Phone: (406) 243-6421. Fax: (406) 243-6425. E-mail:
nunberg{at}selway.umt.edu.
Journal of Virology, March 2001, p. 2741-2752, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2741-2752.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yang, X., Lipchina, I., Cocklin, S., Chaiken, I., Sodroski, J.
(2006). Antibody Binding Is a Dominant Determinant of the Efficiency of Human Immunodeficiency Virus Type 1 Neutralization. J. Virol.
80: 11404-11408
[Abstract]
[Full Text]
-
Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H., Makizumi, K., Nakashima, T., Osatomi, K., Tokiyoshi, S., Matsushita, S., Yamamoto, N., Honda, M.
(2006). Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif.. J. Virol.
80: 5552-5562
[Abstract]
[Full Text]
-
Skrabal, K., Saragosti, S., Labernardiere, J.-L., Barin, F., Clavel, F., Mammano, F.
(2005). Human Immunodeficiency Virus Type 1 Variants Isolated from Single Plasma Samples Display a Wide Spectrum of Neutralization Sensitivity. J. Virol.
79: 11848-11857
[Abstract]
[Full Text]
-
Beddows, S., Schulke, N., Kirschner, M., Barnes, K., Franti, M., Michael, E., Ketas, T., Sanders, R. W., Maddon, P. J., Olson, W. C., Moore, J. P.
(2005). Evaluating the Immunogenicity of a Disulfide-Stabilized, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. J. Virol.
79: 8812-8827
[Abstract]
[Full Text]
-
Pistello, M., Matteucci, D., Giannecchini, S., Bonci, F., Sichi, O., Presciuttini, S., Bendinelli, M.
(2003). Evolution of Two Amino Acid Positions Governing Broad Neutralization Resistance in a Strain of Feline Immunodeficiency Virus over 7 Years of Persistence in Cats. CVI
10: 1109-1116
[Abstract]
[Full Text]
-
Polonis, V. R., Souza, M. S. d., Darden, J. M., Chantakulkij, S., Chuenchitra, T., Nitayaphan, S., Brown, A. E., Robb, M. L., Birx, D. L.
(2003). Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Resistance Is Associated with the Syncytium-Inducing Phenotype and Lower CD4 Cell Counts in Subtype CRF01_AE-Infected Patients. J. Virol.
77: 8570-8576
[Abstract]
[Full Text]
-
Herrera, C., Spenlehauer, C., Fung, M. S., Burton, D. R., Beddows, S., Moore, J. P.
(2002). Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site. J. Virol.
77: 1084-1091
[Abstract]
[Full Text]
-
Villinger, F., Mayne, A. E., Bostik, P., Mori, K., Jensen, P. E., Ahmed, R., Ansari, A. A.
(2002). Evidence for Antibody-Mediated Enhancement of Simian Immunodeficiency Virus (SIV) Gag Antigen Processing and Cross Presentation in SIV-Infected Rhesus Macaques. J. Virol.
77: 10-24
[Abstract]
[Full Text]
-
Poignard, P., Moulard, M., Golez, E., Vivona, V., Franti, M., Venturini, S., Wang, M., Parren, P. W. H. I., Burton, D. R.
(2002). Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies. J. Virol.
77: 353-365
[Abstract]
[Full Text]
-
Pantophlet, R., Ollmann Saphire, E., Poignard, P., Parren, P. W. H. I., Wilson, I. A., Burton, D. R.
(2002). Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. J. Virol.
77: 642-658
[Abstract]
[Full Text]
-
Schulke, N., Vesanen, M. S., Sanders, R. W., Zhu, P., Lu, M., Anselma, D. J., Villa, A. R., Parren, P. W. H. I., Binley, J. M., Roux, K. H., Maddon, P. J., Moore, J. P., Olson, W. C.
(2002). Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein. J. Virol.
76: 7760-7776
[Abstract]
[Full Text]
-
Giannecchini, S., Isola, P., Sichi, O., Matteucci, D., Pistello, M., Zaccaro, L., Del Mauro, D., Bendinelli, M.
(2002). AIDS Vaccination Studies Using an Ex Vivo Feline Immunodeficiency Virus Model: Failure To Protect and Possible Enhancement of Challenge Infection by Four Cell-Based Vaccines Prepared with Autologous Lymphoblasts. J. Virol.
76: 6882-6892
[Abstract]
[Full Text]
-
Follis, K. E., Larson, S. J., Lu, M., Nunberg, J. H.
(2002). Genetic Evidence that Interhelical Packing Interactions in the gp41 Core Are Critical for Transition of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein to the Fusion-Active State. J. Virol.
76: 7356-7362
[Abstract]
[Full Text]
-
Chakrabarti, B. K., Kong, W.-p., Wu, B.-y., Yang, Z.-Y., Friborg, J., Ling, X., King, S. R., Montefiori, D. C., Nabel, G. J.
(2002). Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization. J. Virol.
76: 5357-5368
[Abstract]
[Full Text]
-
Zhang, P. F., Bouma, P., Park, E. J., Margolick, J. B., Robinson, J. E., Zolla-Pazner, S., Flora, M. N., Quinnan, G. V. Jr
(2002). A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response. J. Virol.
76: 644-655
[Abstract]
[Full Text]
-
Lu, M., Stoller, M. O., Wang, S., Liu, J., Fagan, M. B., Nunberg, J. H.
(2001). Structural and Functional Analysis of Interhelical Interactions in the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein by Alanine-Scanning Mutagenesis. J. Virol.
75: 11146-11156
[Abstract]
[Full Text]
-
Verrier, F., Nadas, A., Gorny, M. K., Zolla-Pazner, S.
(2001). Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6. J. Virol.
75: 9177-9186
[Abstract]
[Full Text]
-
Moore, J. P., Parren, P. W. H. I., Burton, D. R.
(2001). Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development. J. Virol.
75: 5721-5729
[Full Text]